Patent · US Expired

Tumor antigens and CTL clones isolated by a novel procedure

US7351409B2 · kind B2 · utility

1Cited by

3References

2Claims

0Family size

Assignee

LUDWIG INSTITUTE FOR CANCER RESEARCH LTD · GB

Inventors

Pascal Chaux · Brussels, BE
Rosalie Luiten · Abcoude, NL
Nathalie Demotte · Brussels, BE
Marie-Therese Duffour · Paris, FR
Christophe Lurquin · Brussels, BE
Catie Traversari · Milano, IT
Vincent Stroobant · Brussels, BE
Guy R. Cornelis · Kraainem, BE
Thierry Boon-Falleur · Brussels, BE
Pierre van der Bruggen · Brussels, BE
Erwin Schultz · Erlangen, DE
Guy Warnier · Brussels, BE

Key dates

Filing date	Jan 7, 2004
Grant date	Apr 1, 2008
Priority date	—
Expiry date	Aug 8, 2025

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61P35/00
WIPO fieldBiotechnology
WIPO sectorChemistry

Abstract

The present invention relates to isolation of cytotoxic T lymphocyte (CTL) clones. In particular, the present invention relates to isolated CTL clones that are specific for proteins of the MAGE family. The CTL clones of the present invention have been isolated by successive steps of stimulation and testing of lymphocytes with antigen presenting cells which present antigens derived from different expression systems, e.g., from recombinant Yersinia, recombinant Salmonella, or recombinant viruses. The present invention further relates to antigenic peptides as well as the peptide/HLA complexes which are recognized by the isolated CTL clones.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.